ArticleAnnals of the American Thoracic Society2015
Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.
Article in Annals of the American Thoracic Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03938298 (Substudy of Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation), which is not on this map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Substudy of Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (ESTxENDS): Pulmonary Function Substudy (PulmENDS)
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Multiple breath washout in primary ciliary dyskinesia: a systematic review of the literature.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Outcome measures for airway clearance techniques in children with chronic obstructive lung diseases: a systematic review.Respiratory research · 2020Pooled it
- An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.BMC pulmonary medicine · 2020Trial
- Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational Study.Annals of the American Thoracic Society · 2025Observational
- Pulmonary function in children post-empyema: spirometryERJ open research · 2025Article
- Small airway disease as a key factor in COPD: new perspectives and insights.Frontiers in medicine · 2025Review
- Interpretation of pulmonary function tests in children.BJA education · 2023Review
- Nationwide lung function monitoring from infancy in newborn-screened children with cystic fibrosis.ERJ open research · 2023Article
- The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting.Respiratory research · 2023Observational
- Computed cardiopulmonography and the idealized lung clearance index, iLCIJournal of applied physiology (Bethesda, Md. : 1985) · 2023Article
- Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass.Frontiers in pharmacology · 2023Article
- Dynamic Perfluorinated Gas MRI Shows Improved Lung Ventilation in People with Cystic Fibrosis after Elexacaftor/Tezacaftor/Ivacaftor: An Observational Study.Journal of clinical medicine · 2022Article
- Breath detection algorithms affect multiple-breath washout outcomes in pre-school and school age children.PloS one · 2022Article
- Association between insurance variability and early lung function in children with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Observational
- Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?Therapeutic advances in chronic disease · 2022Article
- Better late than never: correcting the error in the Exhalyzer nitrogen washout system.Journal of applied physiology (Bethesda, Md. : 1985) · 2021Article
- The Association between IgG and Disease Severity Parameters in CF Patients.Journal of clinical medicine · 2021Article
- Sensitive structural and functional measurements and 1-year pulmonary outcomes in pediatric cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
- Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary.Annals of the American Thoracic Society · 2021Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 16 institutions in 6 countries.
Funding
Abstract
The lung clearance index (LCI) is a lung function parameter derived from the multiple-breath washout (MBW) test. Although first developed 60 years ago, the technique was not widely used for many years. Recent technological advances in equipment design have produced gains in popularity for this test among cystic fibrosis (CF) researchers and clinicians, particularly for testing preschool-aged children. LCI has been shown to be feasible and sensitive to early CF lung disease in patients of all ages from infancy to adulthood. A workshop was convened in January 2014 by the North American Cystic Fibrosis Foundation to determine the readiness of the LCI for use in multicenter clinical trials as well as clinical care. The workshop concluded that the MBW text is a valuable potential outcome measure for CF clinical trials in preschool-aged patients and in older patients with FEV1 in the normal range. However, gaps in knowledge about the choice of device, gas, and standardization across systems are key issues precluding its use as a clinical trial end point in infants. Based on the current evidence, there are insufficient data to support the use of LCI or MBW parameters in the routine clinical management of patients with CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.